ClinicalTrials.gg
Status unknownNCT03963271VIGILANCEUpdated Jul 7, 2021

Noninvasive Electrocardiographic Imaging for Individuals at Risk for Apparently Idiopathic Ventricular Fibrillation.

An observational study in Ventricular Fibrillation, Ventricular Arrythmia and Polymorphic Ventricular Tachycardia, sponsored by Maastricht University Medical Center. Status unknown at 3 sites in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-07-07.

Sponsored by Maastricht University Medical Center · Observational

How we know

The sponsor has not verified this record recently (last verified Jul 2021), so the status shown — last known as Enrolling by invitation — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
500
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Ventricular Fibrillation with a site in Netherlands — 6 open to participants now, 6 under way, 1 of them phase 3. Ventricular Fibrillation · Netherlands.

Started
2019
the only one that year
Observational
6 of 17
2 open now
Registered
11th of 17
by date
Lead sponsor
2 of 17
Maastricht University Medical Center

Among the 17 studies in Ventricular Fibrillation with a site in Netherlands, this one is the only one that started in 2019, is one of 6 observational ones, and was the 11th registered.

Ventricular Fibrillation

186 studies on the registry are indexed under Ventricular Fibrillation; 37 are open to participants now.

Browse Ventricular Fibrillation studies →

Open to participants now

6 of the 17 studies in Ventricular Fibrillation with a site in Netherlands are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 22 Ventricular Fibrillation studies recruiting now, 19 (86%) set no upper age limit and none (0%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Ventricular Fibrillation with a site in Netherlands, or all of them as a file.
02

Study summary

This study aims to evaluate the electrophysiological properties of the heart conduction system in patients with unexplained polymorphic ventricular tachycardia (VT) and/or ventricular fibrillation (VF), in patients with specific genetic mutations regarding sudden cardiac death or sudden cardiac arrest, in their family members and in a control cohort. The electrophysiological properties will be measured with the relatively new technique ECG-Imaging (ECGI).

Also a National Dutch registry for patients with unexplained polymorphic VT and/or VF and their family members will be created.

By combining the data from the registry and the results of ECGI, The investigators hope to identity risk markers for patients at higher risk for apparently idiopathic ventricular fibrillation, and use these for an adapted flow chart for the 'general'population of patients at risk for unexplained polymorphic VT and/or VF. The investigators aim to be able to identify patients before the first arrhythmic event, and aim for better treatment strategies in the future.

Read the detailed description

ECGI combines electrical body-surface mapping with 256 electrodes placed on the thorax with a CT-scan obtaining the anatomy of the heart and torso, hereby able to reconstruct local electrograms, activation and recovery times. In recent research, ECGI provided numerous extra insights into normal cardiac electrophysiology, but also electrophysiological disorders and disease. The results strongly suggest that ECGI can play a pivotal role in further characterizing arrhythmia mechanisms, therefore could do so for polymorphic VT or idiopathic VF leading to diagnosis and treatment improvement. Moreover, ECGI seems to have the potential to detect arrhythmogenic substrate in individuals before their first event, offering the possibility to diagnose and treat patients before sudden cardiac arrest occurs.

In the VIGILANCE study:

  1. ECGI will be used to noninvasively characterize the epicardial electrophysiological substrate and triggers of:

    • Patients with unexplained polymorphic VT and VF,
    • Index patients of family cohorts with a specific genetic mutation related to arrhythmogenesis, at high risk for unexplained polymorphic VT and/or VF.
    • Family members,
    • A control cohort. Results will be evaluated for risk stratification.
  2. All unexplained polymorphic VT and/or VF patients and their family members will be asked to participate in a National Dutch registry, and these date will be analysed to determine their prognostic value in terms of arrhythmia risk
03

Conditions studied

  • Ventricular Fibrillation
  • Ventricular Arrythmia
  • Polymorphic Ventricular Tachycardia
  • Sudden Cardiac Death
  • Heart Arrest
  • Cardiovascular Diseases
  • Cardiac Arrhythmia
  • Genetic Disease
  • Idiopathic Ventricular Fibrillation
  • Cardiac Arrest

Keywords

  • idiopathic ventricular fibrillation
  • polymorphic ventricular tachycardia
  • body surface potential mapping
  • ECG Imaging
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

patients seen at the outpatient clinic at the department of cardiology or (cardio)genetics, patients admitted to the ward of cardiology or the intensive care unit.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

In order to be eligible to participate in this study, a subject must be ≥ 18 years old and meet one of the following criteria:

  • All unexplained polymorphic VT or VF survivors in whom known structural myocardial, respiratory, metabolic and toxicological causes have been excluded through clinical evaluation", with/without a genetic mutation. NB. If results of a diagnostic tests show minor abnormalities but insufficient for a specific diagnosis, this is no exclusion criterion.
  • Selected family members of these patients*
  • Control subjects with structurally normal hearts with a clinical indication for a cardiac CT scan.

    • All 1st and 2nd degree family members being in contact with the cardiologist/treating physician as part of cascade screening will be contacted as described in chapter 11.2.2.

Family members must be in adequate health to be able to travel to the hospital for research purposes.

3rd degree family members can also be contacted as described in chapter 11.2.2 if at least one of the following criteria is met:

  • The family member has the same genetic mutation as index patient, or;
  • The family member has demonstrated ventricular arrhythmias, or;
  • The clinician has a very strong suspicion of ventricular arrhythmias in the family member.

Exclusion criteria

Exclusion Criteria:

A potential subject who meets any of the following criteria will be excluded from participation in this study:

  • A known strong reaction against electrode attachment or contrast agent.
  • Any serious medical condition, which in the opinion of the investigator, may adversely affect the safety and/or effectiveness of the participant or the study.
  • Pregnancy, nursing or planning to be pregnant.
  • Subject has an estimated (eGFR) of \<30mL/min/1.73m2

    , using the MDRD calculation

  • Unability to give .
  • Family members of patients with unexplained polymorphic VT/VF, who have severe cardiac abnormalities and/or disease not related to the symptoms or phenotype of the index patient, and which may have a negative influence on results of ECGI according to local investigators.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
500 participants (estimated)
Target follow-up
3 Years
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • Patients with unexplained polymorphic VT and/or VF

    1. Unexplained polymorphic VT and/or VF patients. 2. Patients with VF and the DPP6 risk haplotype, reported by the AUMC team. 3. The Worm population of patients with a SCN5A founder mutation and other conspiring genetic variants at MUMC+

    Diagnostic Test: ECG-Imaging

  • Family members

    Family members of index patients of group(s) mentioned above

    Diagnostic Test: ECG-Imaging

  • Control group

    Control subjects with structurally normal hearts with an indication for a cardiac CT,

    Diagnostic Test: ECG-Imaging

Interventions

  • Diagnostic testECG-Imaging

    A body surface potential mapping and a cardiac + low dose CT-scan.

06

What researchers measure

Primary outcomes

  1. ECG-Imaging outcome: epicardial potentials

    reconstructed epicardial potentials, represented in mV over time(s).

    Time frame: 3 years

  2. ECG-Imaging outcome: activation and repolarization maps

    Activation and repolarization maps. These are made by measuring acivation and repolarization times from the reconstructed potentials in miliseconds. Then local activation and recovery times are plotted on a CT-derived heart mesh. The entire activation and repolarization of the epicardium of the heart can be visualized this way.

    Time frame: 3 years

Secondary outcomes

  1. (Possible) Prognostic risk factors for recurrent ventricular arrhythmias

    possible risk factors, found in the registry, given as odds/hazard ratio.

    Time frame: 3 years

  2. Recurrence of ventricular arrhythmias

    documentation over the period of follow-up, if studysubjects had a recurrence of ventricular arrythmia(s), presented as number of events over a time period.

    Time frame: 3 years

07

Study locations

3 sites
  • Maastricht Universite Medical Centre
    Maastricht, Nederland, Netherlands
  • Amsterdam University medical Centre, location AMC
    Amsterdam, Netherlands
  • University Medical Centre Utrecht
    Utrecht, Netherlands
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2019 (actual). Primary completion is estimated for Apr 2023, 48 months after the start.

Of 28 observational studies under Ventricular Fibrillation, half reached primary completion within 74 months of starting (the median), counting those still running; a quarter within 39. This study's planned 48 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 23, 2019
First posted
May 24, 2019
StartActual
Apr 10, 2019
Primary completionEst.
Apr 10, 2023
CompletionEst.
Apr 10, 2023
Last update
Jul 7, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 7, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03963271
Responsible party
Sponsor
First posted
May 24, 2019
Start date
Apr 10, 2019
Primary completion
Apr 10, 2023 (estimated)
Completion
Apr 10, 2023 (estimated)
Last update
Jul 7, 2021

Study contacts

Paul Volders, MD, PhD
principal investigator · Maastricht University Medical Centre

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion